Results 21 to 30 of about 75,353,973 (171)

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose [PDF]

Pharmaceutics, 2023
Background: The effects of various dosages and treatment regimens on intravitreal aflibercept concentrations and the proportion of free vascular endothelial growth factor (VEGF) to total VEGF were evaluated using a drug and disease assessment model.
Daniele Veritti, Valentina Sarao, Francesco Di Bin, Paolo Lanzetta   +3 more
doaj   +2 more sources

Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration from China: 48-week results from the PULSAR trial [PDF]

International Journal of Retina and Vitreous
Background PULSAR (NCT04423718) was a global, phase 3, randomized, double-masked, non-inferiority study of adults with neovascular age-related macular degeneration (nAMD).
Xiaodong Sun, Hong Dai, Youxin Chen, Xufang Sun, Liming Tao, Jun Xiao, Mei Han, Mingwei Zhao, Li Wang, Andrea Schulze, Ursula Maria Schmidt-Ott, Min Zhao, Xin Zhang, Zhaohong Wang, Sergio Leal, Wenbin Wei, on behalf of the PULSAR investigators   +16 more
doaj   +2 more sources

Efficacy of Aflibercept 8 mg in Pretreated Age-Related Macular Degeneration. [PDF]

J Clin Med
This study aims to evaluate the real-world efficacy and safety of aflibercept 8 mg intravitreal injections (IVTs) in pretreated patients with neovascular age-related macular degeneration (nAMD) throughout the first three IVTs. Background: Established anti-vascular-endothelial-growth-factor (anti-VEGF) therapies positively impact the progression of nAMD
Palm C, Zweifel SA, Gabathuler F, Cozzi M, Fasler K.   +4 more
europepmc   +3 more sources

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy

Pharmaceuticals
Purpose: The aim was to compare the short-term outcomes of aflibercept 8 mg and brolucizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Methods: This study included 48 eyes of 48 patients with PCV.
Yoshiko Fukuda, Yoichi Sakurada, Yumi Kotoda, Misa Kimura, Kenji Kashiwagi   +4 more
doaj   +3 more sources

Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US

Ophthalmology and Therapy
Introduction The aim of this study was to compare the estimated direct and indirect costs with aflibercept 8 mg and faricimab in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) over 5 years.
Andreas Kuznik, Anna Coughlan, Amy Pinsent, Hector Toro-Diaz, Steven Sherman, Nimesh Patel   +5 more
doaj   +2 more sources

Initial Response of Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration

Journal of Clinical Medicine
Objectives: To assess the initial anatomical and functional outcomes of switching to aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD) previously treated with anti-vascular endothelial growth factor (VEGF) therapy. Methods: Patients with nAMD previously treated with anti-VEGF drugs were switched to aflibercept 8 mg ...
Chikako Hara, Satoko Fujimoto, Yoko Fukushima, Kaori Sayanagi, Kentaro Nishida, Kazuichi Maruyama, Shigeru Sato, Takatoshi Maeno, Kohji Nishida   +8 more
openaire   +3 more sources

Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US [PDF]

Ophthalmology and Therapy
This is a summary of the original article “Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US”.
Andreas Kuznik, Anna Coughlan, Amy Pinsent, Hector Toro-Diaz, Steven Sherman, Nimesh A. Patel   +5 more
doaj   +2 more sources

Sustainability in medical retina: the environmental impact of using aflibercept 8 mg instead of aflibercept 2 mg in treatment-naïve patients with nAMD

Eye
Abstract Background/Objectives Sustainability is a major concern with the use of intravitreal therapy for neovascular age-related macular degeneration (nAMD), as case numbers rise with the ageing population.
Neil Bowley, Peter Thomas, Sobha Sivaprasad, Robert M. J. Purbrick, Emily Beardmore, Rose Gilbert, Andy Clarke, Thomas J. G. Chase   +7 more
openaire   +3 more sources

Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema [PDF]

Ophthalmology and Therapy
Introduction Aflibercept 8 mg and faricimab provide effective anatomical and visual acuity improvements in diabetic macular edema (DME), although functional recovery may not be fully captured by conventional endpoints.
Feliciana Menna, Mattia Calabro, Antonio Guillot, Laura De Luca, Alessandro Meduri, Antonio Baldascino, Stefano Lupo, Enzo Maria Vingolo   +7 more
doaj   +2 more sources

Faricimab 6 mg Versus Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Protocol-Standardised In Silico Study [PDF]

Pharmaceuticals
Background: Faricimab 6 mg and aflibercept 8 mg permit extended treatment intervals in neovascular age-related macular degeneration (nAMD), but their pivotal programmes used different loading and maintenance schedules.
Georgios D. Panos
doaj   +2 more sources